| Syndrome |
NCT02131025: A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen |
|
|
| Active, not recruiting | 3 | 428 | US, Canada | ABC/DTG/3TC FDC, Ongoing cART regimen | ViiV Healthcare, PPD, GlaxoSmithKline | Infection, Human Immunodeficiency Virus | 04/15 | 10/15 | | |
NCT02343900: Tolerability and Acceptability of an Investigational Eye Drop Formulation (IE) |
|
|
| Enrolling by invitation | 3 | 84 | US | Systane® Gel Drops, Alcon's Systane® Gel Drops, Genteal® Lubricant Gel Drops, Alcon's Genteal® Lubricant Gel Drops, Investigational Eye Drop (IE) | Allergan | Dry Eye | 08/15 | 10/15 | | |
NCT00131560: Safety and Efficacy of T Cell Genetic Immunotherapy for HIV |
|
|
| Active, not recruiting | 2 | 60 | US | VRX496-Modified Autologous T cells | VIRxSYS Corporation | HIV Infection | 11/08 | 06/23 | | |
| Active, not recruiting | 2 | 40 | US | VRX496-transduced autologous CD4 T cells | VIRxSYS Corporation | HIV Infections | 01/09 | 06/23 | | |
NCT00046345: Atazanavir for HIV Infected Individuals: An Early Access Program |
|
|
| No Longer Available | N/A | | US | Atazanavir (BMS-232632) | Bristol-Myers Squibb | HIV Infections | | 07/03 | | |
NCT00511771: A Treatment Investigational New Drug (tIND) Program of Tegaserod in Women With Irritable Bowel Syndrome With Constipation or With Chronic Idiopathic Constipation |
|
|
| No Longer Available | N/A | | US | Tegaserod, Zelnorm | Novartis | Irritable Bowel Syndrome With Constipation, Chronic Idiopathic Constipation | | | | |
NCT00162227: An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection |
|
|
| No Longer Available | N/A | | US | Efavirenz, Sustiva, BMS-561525 | Bristol-Myers Squibb | HIV Infection | 12/10 | 12/10 | | |
NCT00162188: An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection: Canada |
|
|
| No Longer Available | N/A | | Canada | Efavirenz, Sustiva, BMS-561525 | Bristol-Myers Squibb | HIV Infection | 12/10 | 12/10 | | |
NCT01026376: An Expanded Access Program for Decitabine in Patients With Myelodysplastic Syndrome (MDS) |
|
|
| No Longer Available | N/A | | RoW | decitabine | Janssen-Cilag Farmaceutica Ltda., Janssen Korea, Ltd., Korea | Myelodysplastic Syndromes | 11/11 | 11/11 | | |
NCT02097251: An Open-Label Treatment Protocol With UX003 rhGUS Enzyme Replacement Therapy for an Advanced Stage MPS 7 Patient |
|
|
| No Longer Available | N/A | | US | UX003, recombinant human beta glucuronidase, rhGUS | Joyce Fox, Ultragenyx Pharmaceutical Inc | Mucopolysaccharidosis Type 7 | | | | |
NCT01776996: An Expanded Access Protocol for Subjects Who Have Completed Clinical Studies Involving Maraviroc |
|
|
| No Longer Available | N/A | | Europe, RoW | Continued Access Arm | ViiV Healthcare, GlaxoSmithKline | Infection, Human Immunodeficiency Virus | | | | |
NCT00992654: A Treatment Access Program To Provide Maraviroc To Eligible Adult Patients Completing A4001050 Study Until Commercial Availability Of Maraviroc (Celsentri) In India |
|
|
| No Longer Available | N/A | | NA | Open Label Treatment Access: Maraviroc, Maraviroc, Celsentri, Selzentry | ViiV Healthcare, Pfizer | Human Immunodeficiency Virus (HIV) | | | | |
| Active, not recruiting | N/A | 10 | US, Europe | EDI200, APO200 | Edimer Pharmaceuticals | X-linked Hypohidrotic Ectodermal Dysplasia | 03/25 | 03/25 | | |